Core Viewpoint - *ST Meigu's 2025 performance forecast indicates expected revenue of approximately 850 to 1,050 million yuan, with a net loss attributable to shareholders projected between 550 to 390 million yuan. The company anticipates a significant increase in net assets by the end of the period due to the completion of its restructuring plan [1][1]. Group 1 - The company received a civil ruling from the Intermediate People's Court of Xiangyang on December 29, 2025, confirming the completion of its restructuring plan, which has effectively resolved its debt crisis and significantly improved its asset-liability structure [1][1]. - The restructuring involved introducing investors and adjusting equity, leading to a substantial increase in the company's net assets by the end of the reporting period [1][1]. Group 2 - The medical beauty business faces increasing competition and challenges in customer acquisition, resulting in a year-on-year decrease in revenue and profit, prompting the company to make impairment provisions for related assets [1][1]. - The biobased fiber business has not shown effective improvement, leading the company to also make impairment provisions for relevant production lines [1][1].

Company Overview - The company primarily operates in the bio-based fiber and medical beauty sectors [6] - It expects to achieve operating revenue of approximately 850 to 1,050 million yuan in 2025, with a net loss attributable to shareholders ranging from 550 to 390 million yuan [6] Financial Performance - The company has undergone a restructuring process, which has significantly improved its debt situation and asset-liability structure, leading to a substantial increase in net assets by the end of the reporting period [6] - The medical beauty business has faced intensified competition, resulting in a decrease in both revenue and profit, prompting the company to make impairment provisions for related assets [6] - The bio-based fiber business has not shown effective improvement, leading to additional impairment provisions for relevant production lines [6] Revenue and Profit Trends - Historical total revenue and net profit figures indicate fluctuations, with total revenue projected to decline in 2022 and 2023, followed by a recovery in 2024 and 2025 [7] - The year-on-year growth rates for total revenue and net profit have shown significant variability, with a notable decline of 36.92% in 2022 and a projected recovery of 19.77% in 2024 [7]

南财智讯1月29日电，*ST美谷发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损3.90亿元—5.50亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损5.50 亿元—7.80亿元。公司预计2025年实现营业收入约8.5至10.5亿元，归属于上市公司股东的净利润亏损约 5.5至3.9亿元，预计期末净资产转正并大幅增长，主要原因如下：1、2025年12月29日，公司收到湖北省 襄阳市中级人民法院（以下简称"襄阳中院"）送达的（2025）鄂06破17号之一《民事裁定书》，鉴于相 关事项已达到《奥园美谷科技股份有限公司重整计划》（以下简称《重整计划》）第七部分第四条规定 的执行完毕标准，《重整计划》已经执行完毕，襄阳中院裁定终结公司重整程序。在重整程序中，公司 通过引入重整投资人、实施出资人权益调整等方式，有效化解了公司债务危机，极大地改善了公司资产 负债结构，大幅提高了公司期末净资产。2、报告期内，医疗美容业务市场竞争越趋激烈、客户开拓难 度加大，公司医疗美容业务营业收入和利润同比有所减少，公司对相关资产计提了减值准备；生物基纤 维业务经营未得到有效改善，公司对相关生 ...

Group 1 - The core viewpoint of the article highlights that *ST Meigu (SZ 000615) held its 29th meeting of the 11th Board of Directors on December 1, 2025, to review the proposal for the reappointment of the auditing institution for the fiscal year 2025 [1] - For the first half of 2025, the revenue composition of *ST Meigu shows that medical beauty services accounted for 57.47%, bio-based fibers accounted for 38.54%, and other services accounted for 3.99% [1] - As of the time of reporting, *ST Meigu has a market capitalization of 3.2 billion yuan [1]

Group 1 - The core point of the article is that *ST Meigu (SZ 000615) held its 27th meeting of the 11th Board of Directors on November 5, 2025, to discuss the proposal for the third extraordinary shareholders' meeting in 2025 [1] - For the first half of 2025, *ST Meigu's revenue composition is as follows: medical beauty services accounted for 57.47%, bio-based fibers accounted for 38.54%, and others accounted for 3.99% [1] - As of the report date, *ST Meigu has a market capitalization of 3 billion yuan [1]